Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
OwnerKenneth L. Rinehart, Tong Zhouinventors
Life of this patent
Estimating the term…
Abstract
Five new nucleophile substituted ecteinascidin (Et) compounds have been isolated from extracts of Ecteinascidia turbinata. These compounds have been purified by chromatographic techniques and their structures and bioactivities have been determined. The five nucleophile substituted Et compounds have been designated herein as Et 802 (1), Et 788 (2), Et 760 (3), Et 858 (4) and Et 815 (5). Also obtained were three new N-oxide ecteinascidin compounds, which have been designated herein as Et 717 (6), Et 775 (7) and Et 789 (8). Some of these newly discovered Et compounds show exceedingly potent cytotoxicity against L1210.
Claims27
Substantially pure Ecteinascidin 717, free of the cellular debris of Ecteinascidia turbinata, said compound having the following structure:
- ##STR2##
Substantially pure Ecteinascidin 815, free of the cellular debris of Ecteinascidia turbinata, said compound having the following structure:
Substantially pure Ecteinascidin 832, free of the cellular debris of Ecteinascidia turbinata, said compound having the following structure:
Substantially pure Ecteinascidin 802, free of the cellular debris of Ecteinascidia turbinata, said compound having the following structure:
Substantially pure Ecteinascidin 788, free of the cellular debris of Ecteinascidia turbinata, said compound having the following structure:
Substantially pure Ecteinascidin 760, free of the cellular debris of Ecteinascidia turbinata, said compound having the following structure:
Substantially pure Ecteinascidin 858, free of the cellular debris of Ecteinascidia turbinata, said compound having the following structure:
Substantially pure Ecteinascidin 789, free of the cellular debris of Ecteinascidia turbinata, said compound having the following structure:
Substantially pure Ecteinascidin 775, free of the cellular debris of Ecteinascidia turbinata, said compound having the following structure:
A pharmaceutical or veterinary composition comprising an effective antitumor amount of the substantially pure compound designated herein as Et 717 and a pharmaceutically acceptable carrier, diluent or excipient, said compound having the following structure:
A pharmaceutical or veterinary composition comprising an effective antitumor amount of the substantially pure compound designated herein as Et 815 and a pharmaceutically acceptable carrier, diluent or excipient, said compound having the following structure:
A pharmaceutical or veterinary composition comprising an effective antitumor amount of the substantially pure compound designated herein as Et 832 and a pharmaceutically acceptable carrier, diluent or excipient, said compound having the following structure:
A pharmaceutical or veterinary composition comprising an effective antitumor amount of the substantially pure compound designated herein as Et 802 and a pharmaceutically acceptable carrier, diluent or excipient, said compound having the following structure:
A pharmaceutical or veterinary composition comprising an effective antitumor amount of the substantially pure compound designated herein as Et 788 and a pharmaceutically acceptable carrier, diluent or excipient, said compound having the following structure:
A pharmaceutical or veterinary composition comprising an effective antitumor amount of the substantially pure compound designated herein as Et 760 and a phaimaceutically acceptable carrier, diluent or excipient, said compound having the following structure:
A pharmaceutical or veterinary composition comprising an effective antitumor amount of the substantially pure compound designated herein as Et 858 and a pharmaceutically acceptable carrier, diluent or excipient, said compound having the following structure:
A pharmaceutical or veterinary composition comprising an effective antitumor amount of the substantially pure compound designated herein as Et 789 and a pharmaceutically acceptable carrier, diluent or excipient, said compound having the following structure:
A pharmaceutical or veterinary composition comprising an effective antitumor amount of the substantially pure compound designated herein as Et 775 and a pharmaceutically acceptable carrier, diluent or excipient, said compound having the following structure:
A method of treating a patient suffering from a mammalian tumor comprising administering to said patient, an effective antitumor amount of the substantially pure compound designated herein as Et 717 and a pharmaceutically acceptable carrier, diluent or excipient, said compound having the following structure:
A method of treating a patient suffering from a mammalian tumor comprising administering to said patient, an effective antitumor amount of the substantially pure compound designated herein as Et 815 and a pharmaceutically acceptable carrier, diluent or excipient, said compound having the following structure:
A method of treating a patient suffering from a mammalian tumor comprising administering to said patient, an effective antitumor amount of the substantially pure compound designated herein as Et 832 and a pharmaceutically acceptable carrier, diluent or excipient, said compound having the following structure:
A method of treating a patient suffering from a mammalian tumor comprising administering to said patient, an effective antitumor amount of the substantially pure compound designated herein as Et 802 and a pharmaceutically acceptable carrier, diluent or excipient, said compound having the following structure:
A method of treating a patient suffering from a mammalian tumor comprising administering to said patient, an effective antitumor amount of the substantially pure compound designated herein as Et 788 and a pharmaceutically acceptable carrier, diluent or excipient, said compound having the following structure:
A method of treating a patient suffering from a mammalian tumor comprising administering to said patient, an effective antitumor amount of the substantially pure compound designated herein as Et 760 and a pharmaceutically acceptable carrier, diluent or excipient, said compound having the following structure:
A method of treating a patient suffering from a mammalian tumor comprising administering to said patient, an effective antitumor amount of the substantially pure compound designated herein as Et 858 and a pharmaceutically acceptable carrier, diluent or excipient, said compound having the following structure:
A method of treating a patient suffering from a mammalian tumor comprising administering to said patient, an effective antitumor amount of the substantially pure compound designated herein as Et 789 and a pharmaceutically acceptable carrier, diluent or excipient, said compound having the following structure:
A method of treating a patient suffering from a mammalian tumor comprising administering to said patient, an effective antitumor amount of the substantially pure compound designated herein as Et 775 and a pharmaceutically acceptable carrier, diluent or excipient, said compound having the following structure:
Dependencies are inferred from the claim text.